

**BUKTI KORESPONDENSI JURNAL**

*L. vannamei Shells Reduces Atherogenic Index  
of Preclinical Study in Diabetic Rats*

## **BUKTI KORESPONDENSI**

- 1. Cover Letter**
- 2. Submitted Article**
- 3. Koreksi dari Reviewer**
- 4. Point-to-point Response (Jawaban Review)**
- 5. Email Revision Confirmation**
- 6. Email Final Proof**
- 7. Published Article**

# Cover Letter

Mediterranean Journal of Nutrition and Metabolism  
Prof. Maurizio Battino, PhD, DSc, MD (Hon), Editor-in-Chief

**Concerning:** Submission paper to Mediterranean Journal of Nutrition and Metabolism

Dear Prof. Maurizio Battino, PhD, DSc, MD (Hon),

Please find enclosed our manuscript entitled “*L. vannamei* shells reduces cardiovascular risk factors: A preclinical study in diabetic rats” for editorial consideration and hopefully peer review by Mediterranean Journal of Nutrition and Metabolism. We hereby declare that the content is original and has not been published nor simultaneously submitted to another journal. All authors have been seen and agreed with the submitted version of the manuscript. The corresponding author is responsible for raw data readily availability for presentation to the referees and the editors of Mediterranean Journal of Nutrition and Metabolism, if requested. Furthermore, none of the authors has any conflict of interest in relation to the content of the manuscript.

We hope that our contribution meets your quality requirements, and we look forward to your reply.

Sincerely,

Luthfia Dewi

Department of Nutrition

Universitas Muhammadiyah Semarang, Semarang, Indonesia

E-mail: luthfia@unimus.ac.id

Phone: +62 823 2535 8329

ORCID ID: 0000-0001-5241-2240

# Submitted Article

1 ***L. vannamei* shells reduces cardiovascular risk factors: A preclinical study in**  
2 **diabetic rats**

3  
4 Rr. Annisa Ayuningtyas<sup>1</sup>, Kis Djamiatun<sup>2</sup>, Tri Winarni Agustini<sup>3</sup>, Luthfia Dewi<sup>1, \*</sup>

5  
6 <sup>1</sup>Nutrition Department, Faculty of Nursing and Health Science, Universitas  
7 Muhammadiyah Semarang, Semarang, Indonesia

8 <sup>2</sup>Programme in Medical Education, Faculty of Medicine, Universitas Diponegoro,  
9 Semarang, Indonesia

10 <sup>3</sup>Fish Product Technology, Faculty of Fisheries and Marine Science, Universitas  
11 Diponegoro, Semarang, Indonesia

12  
13 \*Corresponding author:

14 Luthfia Dewi

15 Nutrition Department, Faculty of Nursing and Health Science, Universitas

16 Muhammadiyah Semarang, Semarang, Indonesia

17 Telp: +62 24 76740296

18 Fax: 024 - 76740291

19 E-mail: luthfia@unimus.ac.id

20     **Abstract**

21     **BACKGROUND:** Cardiovascular disease (CVD) appears the fundamental cause of  
22     morbidity and mortality in type 2 diabetes mellitus (T2DM). Improving the level of  
23     lipoprotein ratios using natural ingredient was widely used.

24     **OBJECTIVE:** This study aimed to examine antioxidant source-Litopenaeus vannamei  
25     shell powder (LVSP) to rebalance the lipoprotein ratios in diabetic rats.

26     **METHODS:** A-14 days prior to streptozotocin (STZ) injection, male Wistar rats  
27     (n=30) were evenly grouped into non-intervention (C-), pre-intervention high-fat diet  
28     (C+), pre-intervention high-fat diet with LVSP dose 0.89 g/body weight (BW), pre-  
29     intervention high-fat diet with LVSP dose 1.77 g/BW (T2), and pre-intervention high-  
30     fat diet with astaxanthin 0.09 mg/BW (T3).

31     **RESULTS:** A reduction of LDL, total cholesterol (TC), and TC/HDL, LDL/HDL, and  
32     LDL/TC ratio was observed ( $p<0.001$ ). A negative, strong correlation was found  
33     between the change of adiponectin to the change of TC ( $r=-0.94$ ), LDL ( $r=-0.92$ ),  
34     TC/HDL ( $r=-0.94$ ), LDL/HDL ( $r=-0.91$ ), and LDL/TC ( $r=-0.82$ ). The magnitude of  
35     improvement showed a dose-dependent manner, and the high dose delineated a  
36     comparable effect to astaxanthin.

37     **CONCLUSION:** The present study brought a profound finding on the potential of LV  
38     to reduce cardiovascular risk factors in T2DM rats.

39

40     **Keywords:** antioxidant, diabetes, lipid, lipoprotein ratio

41

## 42 **1. Introduction**

43 People with T2DM have two to three folds higher in morbidity and mortality  
44 caused by CVD, compared to those who non-T2DM [1, 2]. T2DM *per se* causes  
45 qualitatively, quantitatively, and kinetically abnormalities on the lipid profiles, thus  
46 leads to vascular complication [3, 4]. It has been concluded in a systematic review and  
47 meta-analysis that increasing of total cholesterol is a strong risk factor for coronary  
48 heart disease [5]. Lipoproteins play a fundamental role as an intermediary of dietary  
49 lipid absorption and transportation from intestine into peripheral tissue and in reverse  
50 [6]. The question whether the changes of lipoprotein profiles contribute to  
51 cardiovascular disease has been well answered. A significant increases of LDL  
52 deposition in the plasma because of LDL catabolism disturbance triggered  
53 atherosclerosis in T2DM patients [7]. Additionally, lipoprotein ratios, also called  
54 atherogenic indices, are used to predict cardiovascular diseases in clinical practice [8,  
55 9, 10, 11].

56 Adiponectin, an adipokine secreted by adipose tissues, exerts as an insulin-  
57 sensitizing hormone and lipoprotein protector [9]. Adiponectin receptors (Adipo R1  
58 and Adipo R2) upregulate AMP-kinase activity, *peroxisome* proliferator-activated  
59 receptor (PPAR)  $\alpha$  ligand, and thus stimulate glucose uptake and lipid metabolism [12].  
60 Epidemiological studies reported that serum adiponectin negatively correlated with

61 cardiovascular events [13, 14]. The interplay of adiponectin in lipoprotein metabolism  
62 remains to be explored. The variety result of association between circulating  
63 adiponectin and LDL among studies has been summarised in the published review [15].

64 Whiteleg or *vannamei* shrimp (*Litopenaeous vannamei*), is one of high-demand  
65 export commodities in Indonesia, in the form of headless frozen shrimp. Approximately  
66 40-45% of the body shrimp considered as by-product, including their shells [16]. The  
67 shrimp shells contain some beneficial nutrients, such as chitin (15%–40%), protein  
68 (20%–40%), calcium and magnesium carbonate (20%–50%), and other micronutrients  
69 such as astaxanthin, lipids, and minerals [17]. Majority of pigments in crustacean shells  
70 is astaxanthin, representing 74-98% of total pigments [18]. To date, functional foods  
71 still become the main concern to manage the clinical conditions. For example,  
72 astaxanthin-extracted from shrimp shell improved the nephropathy in diabetic animals  
73 [19]. Whether the effect of shrimp shell powder to ameliorate lipoprotein profiles in  
74 diabetic condition yet to be determined.

75 The study inspecting whiteleg shrimp shell on reducing CVD risk in T2DM  
76 Wistar rats has been recently investigated [20]. Here, we further analysed the  
77 lipoprotein ratios after treated by LVSP. This study primarily aimed to examine the  
78 cardioprotective effect of *L. vannamei* shrimp shell powder (LVSP) in LDL, TC, and



79 lipoprotein ratios. The secondary outcome of the present study was to correlate  
80 adiponectin changes with the biomarkers.

81

## 82 **2. Materials and methods**

### 83 *2.1. Materials*

84 *L. vannamei* shrimp shells were obtained from PT. Misaja Mitra, Tayu, Pati,  
85 Indonesia. The shells were cleaned from dirt and the remaining flesh using running  
86 water. Second, the clean shells were kept using a polyethylene bag in a freezer with the  
87 optimum temperature around  $-18^{\circ}\text{C}$  -  $(-10)^{\circ}\text{C}$  until were used. Before the shells being  
88 crushed using a food processor and sifted using the 60-mesh sieve, the shells were dried  
89 using freeze-drying method in Laboratorium Mikrobiologi PAU, Universitas Gajah  
90 Mada, Yogyakarta for 3-4 days ( $-40^{\circ}\text{C}$ ). The sifted LVSP was stored in a dark bottle  
91 coated with aluminium foil outside and an oxygen scavenger inside and kept in a  
92 refrigerator at  $4^{\circ}\text{C}$ . Each bottle contained the ratio 1:1:1 of carapace: abdomen: thorax.

93

### 94 *2.2. Study design and animals*

95 The study protocol to assess the cardioprotective effect of LVSP in STZ-  
96 induced rats is shown in Fig. 1. Male Wistar rats (n=30) were grouped into non-  
97 intervention (C-), pre-intervention high-fat diet (HFD) (C+), pre-intervention HFD-

98 STZ and intervened by LVSP dose 0.89 g/BW, pre-intervention HFD and intervened  
99 by LVSP dose 1.77 g/BW (T2), and pre-intervention HFD and intervened by  
100 astaxanthin 0.09 mg/BW (T3) (AST; ASTHIN® Force 4, SOHO, Indonesia). LVSP  
101 and AST were orally supplemented by gavage once a day in the morning for 21 days.  
102 LVSP and AST diluted in 0.5% CMC–Na (Sigma-Aldrich, USA) till the solution  
103 became homogeneous. C– and C+ groups received no treatment.

104 The rats were purchased and kept in single cage with a 12-h light/dark period at  
105 a temperature of 20°C ± 1°C, in *Laboratorium Hewan Coba*, PSPG UGM, Yogyakarta,  
106 Indonesia. This study has been extensively reviewed and approved by the ethics  
107 committee with No. 118/EC/H/FK-RSDK/X/2018).

108

### 109 *2.3. Induction of T2DM*

110 Four groups, C+, T1, T2, and T3 were induced T2DM in two phases: by HFD  
111 and streptozotocin (STZ). After seven days of acclimatization, HFD (15 g) was given  
112 to these four groups for 14 days. HFD-lard based diet composed which contained 100%  
113 fat (9 kcal/g). The standard diet contained 15% protein, 7% fat, and 78% carbohydrate  
114 (4.35 kcal/g). After HFD phase, the four groups were intraperitoneally injected by STZ  
115 (Nacalai Tesque, Kyoto, Japan) with dosage 45 mg/kg BW (diluted in a citrate buffer)  
116 and nicotinamide (NA; Nacalai Tesque, Kyoto, Japan) with dosage 110 mg/kg BW

117 (diluted in a saline buffer). T2DM happened after three days of injection (data not  
118 shown). The determination of fasting blood glucose level of >13.9 mmol/L were  
119 considered to have T2DM condition [19].

120

#### 121 *2.4. Blood sampling*

122 The plexus retro-orbital blood samples (approximately 3 mL) were taken twice  
123 during study period, after T2DM induction and at the end of the intervention. Before  
124 taken up the blood samples, the rats were fasted for 6-10 h. The blood then centrifuged  
125 at 4000 rpm for 15 min to separate serum and platelets. The serum was used to further  
126 analysis.

127

#### 128 *2.5. Biochemical markers determination*

129 Total cholesterol levels were analysed by the CHOD-PAP method, which used  
130 principle of cholesterol determination after enzymatic hydrolysis and oxidation. The  
131 calorimetric indicator was quinoneimine, and it was generated from 4-aminoantipyrine  
132 and phenol by hydrogen peroxide under the catalytic action of peroxidase (Trinder's  
133 reaction). Determination of LDL levels was done by using CHOD PAP method and  
134 calculated from the combined results of total cholesterol, high density lipoprotein  
135 (HDL), and triglycerides (TG) using the Friedwald equation as follow:

136 
$$\text{LDL} = \text{total cholesterol} - \text{HDL} - \frac{\text{TG}}{5}$$

137 The data of HDL, TG and adiponectin levels have been published [21].

138

139 *2.6. Statistical analysis*

140 Shapiro–Wilk test was used to test the normality of data. The difference between  
141 pre- and post-treatments of all parameters was analysed by the paired t-test when the  
142 data were normally distributed and by the Wilcoxon test when the data were not  
143 normally distributed. The different among five groups of rats were analysed by one-  
144 way ANOVA (if the data were homogeneous) followed by post-hoc Bonferroni. If non-  
145 homogeneity data were found, Kruskal–Wallis test followed by Mann-Whitney U-test  
146 was performed. Correlations were evaluated using the Pearson correlation test (if the  
147 data were normally distributed) and the Spearman test (if the data were not normally  
148 distributed). A significant different was set at level  $p < 0.05$ . All statistical analysis was  
149 proceeded using IBM SPSS Statistics 27.0 (IBM Corporation, Armonk, NY).

150

151 **3. Results**

152 The data from 25 rats were analysed in the present study since five animals died  
153 in the middle of experiment. All data were normally distributed ( $p > 0.05$ ). This study  
154 used a single biomarker of adiponectin and HDL from our work that has been published

155 [21]. The data of body weight (Fig. 2A) and food intake (Fig. 2B) were obtained starting  
156 from STZ injection. The food intake of diabetic animals without interventions (C+)  
157 increased by 32% ( $p<0.05$ ) in week 3 with a progressive decline of body weight. The  
158 treatment groups experienced a growing body weight the same trend as a C-.  
159 Furthermore, the group with the intervention of high dose LVSP showed an increasing  
160 the average of food intake ~12% ( $p<0.05$ ) in week 3.

161 The LDL levels in C+, T1, T2, and T3 after T2DM induction increase  
162 significantly compared to C- (Table 1). LVSP treatment markedly reduced LDL levels  
163 in T1 and T2 ( $p<0.001$ ). The higher dose of LVSP showed a better effect on reducing  
164 LDL after T2DM compared to the lower dose, showing a reduction was showed in T2  
165 group, from  $4.4 \pm 0.2$  to  $2.1 \pm 0.2$  mmol/L. The reduction in T2 (-52%) is similar with  
166 the effect of AST. A significant increases of TC levels after T2DM induction was  
167 observed ( $p<0.001$ ). Both low and high dose of LVSP interventions attenuated total  
168 cholesterol by 7 and 30% respectively ( $p<0.001$ ). LVSP with high dose showed a  
169 comparable lowering-effect with AST intervention ( $p>0.05$ ). Lipoprotein ratios in the  
170 present study were indicated by TC-HDL, LDL-HDL, and LDL-TC ratio. Low and high  
171 dose of LVSP significantly decreased the ratio of TC-HDL by 45 and 72%, LDL-HDL  
172 by 57 and 80%, and LDL-TC by 22 and 31% ( $p<0.05$ ). LVSP with high dosage exerted  
173 a comparable effect as AST.

174 A coefficient of determination in all biomarkers with adiponectin was shown in  
175 Fig. 3A-F. By providing LVSP, the change of total cholesterol levels influenced  
176 approximately 72% ( $p < 0.05$ ) of the change adiponectin levels. Furthermore, the linear  
177 interaction in the groups intervened by LVSP between the decreasing LDL/HDL ratio  
178 and increasing adiponectin was shown an approximate 62% ( $p < 0.05$ ). A negative  
179 correlation was also shown by the change of TC/HDL ratio to the change adiponectin,  
180 which approximately 68% ( $p < 0.05$ ) an increasing adiponectin was determined by  
181 TC/HDL ratio.

182

#### 183 **4. Discussion**

184 To our knowledge, the present study provides the further analysis to confirm  
185 the effect of shrimp shells that is considered as by-product to alleviate cardiovascular  
186 disease risk in T2DM [20]. Here, we summarised the findings as follows: (1) LVSP  
187 treatment maintained the body weight in diabetic condition; (2) LVSP improved lipid  
188 profiles; (3) LVSP decreased lipoprotein ratios; (4) negative correlation between  
189 adiponectin and all biomarkers was observed.

190 In the previous study using animal model, the injection of STZ changed body  
191 composition, including body size, which is mimicking people with T2DM [22]. In the  
192 present study, a significant dropped of body weight was shown in the diabetic group

193 without intervention which is likely associated with the impairment of muscle and  
194 splanchnic cells to uptake glucose [23]. We found that LVSP has a capability to sustain  
195 the growth in diabetic state similar with the non-diabetic condition. The body weight  
196 data in this study support our previous work, showing that both of LVSP treatments  
197 increased insulin sensitivity, indicated by decreasing the ratio of TG-HDL [21].

198 The abnormality of lipid profiles in T2DM has been documented in  
199 epidemiological studies [24, 25]. In this animal study, diabetic condition increased the  
200 proportion of LDL to total cholesterol about 45%, delineating 28% higher compared to  
201 non-diabetic group. The LDL increased by 197% in diabetic group after being exposed  
202 by HFD-lard based diet and STZ due to the impairment of insulin sensitivity [21] that  
203 affected the function of LDL-receptor [26]. That LVSP intervention markedly reduced  
204 the LDL levels hypothesised the bioactive components in LVSP (including astaxanthin)  
205 exerts as a hypolipidemic agent in diabetic animals. This result robust the recently  
206 published paper that LVSP attenuated dyslipidaemia in diabetic state [20].

207 The ratio of lipoproteins showed a better prediction on CVD risk compared to  
208 conventional lipid levels [27, 28]. Dietary fat has been known to stimulate lipid  
209 abnormalities in animal study [29]. In the present study, we found that the increasing  
210 of TC/HDL ratio and LDL/HDL ratio in non-diabetic control group due to the raising  
211 total cholesterol and LDL levels was mediated by total energy intake. This may infer

212 the amount of energy intake more affecting to raise total cholesterol and LDL levels  
213 rather than fat content. Of note, in the certain levels, total cholesterol is required for  
214 constructing cell membrane [30]. The increasing LVSP lowered the ratio of TC-HDL,  
215 LDL-HDL, and LDL-TC in dose-dependent levels and the magnitude of ratio reduction  
216 in the high dose LVSP group came approach to astaxanthin supplement. These pre-  
217 clinical results provided the future research of generating powder-based supplement of  
218 LVSP. As expected, the predictors of CVD in the presents study were all negatively  
219 strong correlation with adiponectin levels. The mechanism underlined the correlations  
220 between adiponectin and lipoprotein ratios remains to be elucidated. We hypothesize  
221 the association is mediated by increasing HDL and decreasing TG [15, 21].

222 The effect of shrimp shell on the change of adiponectin levels [21] and the lipid  
223 profiles has been reported before [20]. Of note, the method of shrimp shell processing  
224 in the current study was different with the previous report [20], therefore, the effect of  
225 shrimp shell in the powder form may result the different outcomes. Here, we add the  
226 additional insight that decreasing total cholesterol, TC/HDL ratio, and LDL/HDL ratio  
227 are correlated with increasing adiponectin levels. However, we unable to fully delineate  
228 the causal relationship among the parameters. Since adiponectin has critical role for  
229 endothelium-dependent vasodilation [25], it would be interest to examine whether lipid  
230 profiles have a direct impact on adiponectin levels.



231 As social animals, a single cage might promote stress for rats [31]. Since we  
232 prioritized to measure the amount of food intake of every single rat, we put the animals  
233 in the single house. Furthermore, the male rodents were prone to fighting, thus we  
234 separated the animal in individual house during the intervention periods. Five animals  
235 could not survive up to the sacrifice day, which was caused by very low food intake  
236 and therefore their body weight was shrinkage.

237 In summary, LVSP alleviated the risk of CVD by decreasing LDL, TC,  
238 TC/HDL, LDL/HDL, and LDL/TC in T2DM-induced Wistar rats. High dose of LVSP  
239 1.77 g/BW showed the comparable effect as AST. Whether the higher dose is more  
240 beneficial for lipid profiles in diabetic state requires more animal study. The present  
241 study provided the hypolipidemic effect on T2DM that possible to apply in the human  
242 study.

243

#### 244 **Acknowledgements**

245 The authors thank the laboratory technicians for their participation.

246

#### 247 **Funding statement**

248 The authors report no funding.

249

250 **Conflict of interest**

251 There is no conflict of interest declared.

252

253 **Authors' contributions:**

254 Dewi, L: conceptualization, methodology, software. Ayuningtyas, A: data curation,  
255 writing-original draft preparation. Dewi, L: visualization, investigation. Djamiatun, K:  
256 supervision, Agustini, TW: supervision, Ayuningtyas, A: software, validation. Dewi,  
257 L: writing-reviewing and editing.

258

259 **References**

- 260 [1] Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-  
261 Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors  
262 the same strength? *World J Diabetes*. 2014;5(4):444-70, doi:  
263 10.4239/wjd.v5.i4.444.
- 264 [2] Schmidt AM. Diabetes mellitus and cardiovascular disease. *Arterioscler*  
265 *Thromb Vasc Biol*. 2019;39(4):558-68, doi: 10.1161/atvbaha.119.310961.
- 266 [3] Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al.  
267 Diabetes as a cardiovascular risk factor: an overview of global trends of macro

268 and micro vascular complications. *Eur J Prev Cardiol.* 2019;26(2\_suppl):25-  
269 32, doi: 10.1177/2047487319878371.

270 [4] Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we?  
271 *Diabetologia.* 2015;58(5):886-99, doi: 10.1007/s00125-015-3525-8.

272 [5] Peters SA, Singhateh Y, Mackay D, Huxley RR, Woodward M. Total  
273 cholesterol as a risk factor for coronary heart disease and stroke in women  
274 compared with men: a systematic review and meta-analysis. *Atherosclerosis.*  
275 2016;248:123-31, doi: 10.1016/j.atherosclerosis.2016.03.016.

276 [6] Ginsberg HN. Lipoprotein physiology. *Endocrinol Metab Clin North Am.*  
277 1998;27(3):503-19, doi: 10.1016/s0889-8529(05)70023-2.

278 [7] Yadav NK, Thanpari C, Shrewastwa MK, Mittal RK. Comparison of lipid  
279 profile in type-2 obese diabetics and obese non-diabetic individuals. a hospital  
280 based study from Western Nepal. *Kathmandu Univ Med J (KUMJ).*  
281 2012;10(39):44-7, doi: 10.3126/kumj.v10i3.8017.

282 [8] Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, et al.  
283 Lipoprotein ratios: physiological significance and clinical usefulness in  
284 cardiovascular prevention. *Vasc Health Risk Manag.* 2009;5:757-65, doi.

285 [9] Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ,  
286 Zwinderman AH. LDL-C/HDL-C ratio in subjects with cardiovascular disease

287 and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in  
288 different Dosages And Reverse cholesterol transport) study. *Curr Med Res*  
289 *Opin.* 2005;21(11):1865-74, doi: 10.1185/030079905x74952.

290 [10] Panagiotakos DB, Pitsavos C, Skoumas J, Chrysohoou C, Toutouza M,  
291 Stefanadis CI, et al. Importance of LDL/HDL cholesterol ratio as a predictor  
292 for coronary heart disease events in patients with heterozygous familial  
293 hypercholesterolaemia: a 15-year follow-up (1987-2002). *Curr Med Res Opin.*  
294 2003;19(2):89-94, doi.

295 [11] Quispe R, Elshazly MB, Zhao D, Toth PP, Puri R, Virani SS, et al. Total  
296 cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-  
297 HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in  
298 primary prevention: The ARIC study. *Eur J Prev Cardiol.* 2020;27(15):1597-  
299 605, doi: 10.1177/2047487319862401.

300 [12] Caselli C. Role of adiponectin system in insulin resistance. *Mol Genet Metab.*  
301 2014;113(3):155-60, doi: 10.1016/j.ymgme.2014.09.003.

302 [13] Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius Br. Serum  
303 adiponectin Is a predictor of coronary heart disease: a population-based 10-  
304 year follow-up study in elderly men. *J Clin Endocrinol Metab.*  
305 2007;92(2):571-6, doi: 10.1210/jc.2006-1067.

- 306 [14] Koenig W, Khuseyinova N, Baumert J, Meisinger C, Löwel H. Serum  
307 concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary  
308 heart disease in apparently healthy middle-aged men: results from the 18-year  
309 follow-up of a large cohort from southern Germany. *J Am Coll Cardiol.*  
310 2006;48(7):1369-77, doi: 10.1016/j.jacc.2006.06.053.
- 311 [15] Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism. *Obes*  
312 *Rev.* 2013;14(12):939-49, doi: 10.1111/obr.12064.
- 313 [16] Vázquez JA, Ramos P, Mirón J, Valcarcel J, Sotelo CG, Pérez-Martín RI.  
314 Production of chitin from *Penaeus vannamei* by-products to pilot plant scale  
315 using a combination of enzymatic and chemical processes and subsequent  
316 optimization of the chemical production of chitosan by response surface  
317 methodology. *Mar Drugs.* 2017;15(6), doi: 10.3390/md15060180.
- 318 [17] Khoushab F, Yamabhai M. Chitin research revisited. *Mar Drugs.*  
319 2010;8(7):1988-2012, doi: 10.3390/md8071988.
- 320 [18] Shahidi F, Metusalach, Brown JA. Carotenoid pigments in seafoods and  
321 aquaculture. *Crit Rev Food Sci Nutr.* 1998;38(1):1-67, doi:  
322 10.1080/10408699891274165.

- 323 [19] Sila A, Ghilissi Z, Kamoun Z, Makni M, Nasri M, Bougatef A, et al.  
324 Astaxanthin from shrimp by-products ameliorates nephropathy in diabetic rats.  
325 Eur J Nutr. 2015;54(2):301-7, doi: 10.1007/s00394-014-0711-2.
- 326 [20] Huang CH, Lin CH, Huang HH, Tsai GJ. Development of fermented shrimp  
327 shell product with hypoglycemic and hypolipidemic effects on diabetic rats.  
328 Metabolites. 2022;12(8), doi: 10.3390/metabo12080695.
- 329 [21] Ayuningtyas A, Agustini TW, Djamiatun K. Whiteleg shrimp shell powder  
330 ameliorates adiponectin and triglyceride-to-HDL ratio in type 2 diabetic rats.  
331 NFS. 2020;50(4):617-29, doi: 10.1108/NFS-04-2019-0138.
- 332 [22] Lin YH, Tsai SC, Chuang SJ, Harris MB, Masodsai K, Chen PN, et al. Whole-  
333 life body composition trajectory and longevity: role of insulin. Aging (Albany  
334 NY). 2021;13(7):9719-31, doi: 10.18632/aging.202727.
- 335 [23] Basu A, Basu R, Shah P, Vella A, Johnson CM, Jensen M, et al. Type 2  
336 diabetes impairs splanchnic uptake of glucose but does not alter intestinal  
337 glucose absorption during enteral glucose feeding: additional evidence for a  
338 defect in hepatic glucokinase activity. Diabetes. 2001;50(6):1351-62, doi:  
339 10.2337/diabetes.50.6.1351.

- 340 [24] Ozder A. Lipid profile abnormalities seen in T2DM patients in primary  
341 healthcare in Turkey: a cross-sectional study. *Lipids Health Dis.* 2014;13:183,  
342 doi: 10.1186/1476-511x-13-183.
- 343 [25] Antwi-Baffour S, Kyeremeh R, Boateng SO, Annison L, Seidu MA.  
344 Haematological parameters and lipid profile abnormalities among patients  
345 with type-2 diabetes mellitus in Ghana. *Lipids Health Dis.* 2018;17(1):283,  
346 doi: 10.1186/s12944-018-0926-y.
- 347 [26] Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states:  
348 relationship to atherogenesis. *Diabetes Care.* 1991;14(9):839-55, doi:  
349 10.2337/diacare.14.9.839.
- 350 [27] Zhu L, Lu Z, Zhu L, Ouyang X, Yang Y, He W, et al. Lipoprotein ratios are  
351 better than conventional lipid parameters in predicting coronary heart disease  
352 in Chinese Han people. *Kardiol Pol.* 2015;73(10):931-8, doi:  
353 10.5603/KP.a2015.0086.
- 354 [28] Barzi F, Patel A, Woodward M, Lawes CM, Ohkubo T, Gu D, et al. A  
355 comparison of lipid variables as predictors of cardiovascular disease in the  
356 Asia Pacific region. *Ann Epidemiol.* 2005;15(5):405-13, doi:  
357 10.1016/j.annepidem.2005.01.005.

- 358 [29] Chen B, Huang Y, Zheng D, Ni R, Bernardis MA. Dietary fatty acids alter lipid  
359 profiles and induce myocardial dysfunction without causing metabolic  
360 disorders in mice. *Nutrients*. 2018;10(1), doi: 10.3390/nu10010106.
- 361 [30] Krause MR, Regen SL. The structural role of cholesterol in cell membranes:  
362 from condensed bilayers to lipid rafts. *Acc Chem Res*. 2014;47(12):3512-21,  
363 doi: 10.1021/ar500260t.
- 364 [31] Manouze H, Ghestem A, Poillerat V, Bennis M, Ba-M'hamed S, Benoliel JJ,  
365 et al. Effects of single cage housing on stress, cognitive, and seizure  
366 parameters in the rat and mouse pilocarpine models of epilepsy. *eNeuro*.  
367 2019;6(4), doi: 10.1523/eneuro.0179-18.2019.
- 368
- 369



370 **Table title**

371 Table 1. The effect of LVSP on LDL and TC levels, and lipoprotein ratios. The  
372 significancy different outcomes were analysed from the change post to pre  
373 intervention. C-: non treatment group, C+: diabetic control group, T1: diabetic group  
374 and intervened by LVSP dose 0.89 g/BW, T2: diabetic group and intervened by LVSP  
375 dose 1.77 g/BW, T3: diabetic group and intervened by astaxanthin 0.09 mg/BW.  
376 LVSP: *L. vannamei* shrimp shell powder. The data were written as mean  $\pm$  SD; *p*  
377 value between pre- and post- treatment were analysed using paired t-test.  $\Delta$  (%):  
378 percent changes relative to pre-intervention. Differences among the groups were  
379 analysed using ANOVA followed by post-hoc Bonferroni. \*Represents a significant  
380 different between pre-post intervention. Alphabetical superscripts showed a  
381 significance level of <sup>a</sup>  $p < 0.05$  compared to C-; <sup>b</sup>  $p < 0.05$  compared to C+; <sup>c</sup>  $p < 0.05$   
382 compared to T1; <sup>d</sup>  $p < 0.05$  compared to T2; <sup>e</sup>  $p < 0.05$  compared to T3.

383

384 **Figure captions**


385 Fig. 1. Experimental protocol.

386 Fig. 2. Body weight (g) and food intake (g) starting from HFD-STZ phase (14 days)  
387 to the end of LVSP intervention. LVSP: *L. vannamei* shrimp shell powder. The data  
388 were presented as mean  $\pm$  SD.

389 Fig. 3. Correlation between the changes of adiponectin and TC (A), LDL (B),  
390 LDL/HDL ratio (C), LDL/TC ratio, TC/HDL ratio (E), and food intake (F). The  
391 correlation was taken from the data of groups intervened by LVSP. The change of  
392 value was calculated from the beginning of intervention to the end of intervention.  
393 LVSP: *L. vannamei* shrimp shell powder.  $R^2$ : coefficient of determination.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

Fig. 1.




1 Fig. 2.

A




B




1 Fig. 3.


A




B




C




D



E



F



1 Table 1

	C-	C+	T1	T2	T3
LDL (mmol/L)					
Pre	1.5 ± 0.1	4.4 ± 0.2 <sup>a</sup>	4.0 ± 0.2 <sup>a</sup>	4.4 ± 0.2 <sup>a</sup>	4.3 ± 0.1 <sup>a</sup>
Post	1.6 ± 0.1	4.5 ± 0.2	2.8 ± 0.1	2.1 ± 0.2	1.9 ± 0.1
<i>p</i>	0.008*	0.004*	<0.001*	<0.001*	<0.001*
Δ (%)	9.8 ± 4.2	3.3 ± 1.3	-28.6 ± 4.8 <sup>abde</sup>	-52.3 ± 2.7 <sup>abc</sup>	-55.5 ± 3.5 <sup>abc</sup>
TC (mmol/L)					
Pre	5.4 ± 0.1	9.6 ± 0.3 <sup>a</sup>	9.4 ± 0.2 <sup>a</sup>	9.9 ± 0.3	9.8 ± 0.4
Post	5.5 ± 0.2	9.7 ± 0.3	8.7 ± 0.2	6.9 ± 0.2	6.1 ± 0.3
<i>p</i>	0.017*	0.001*	0.011*	<0.001*	<0.001*
Δ (%)	2.6 ± 1.5	0.7 ± 0.2	-7.4 ± 3.5 <sup>abde</sup>	-30.5 ± 2 <sup>abce</sup>	-37.9 ± 4.7 <sup>abcd</sup>
TC/HDL					
Pre	1.2 ± 0.0	6.6 ± 0.4 <sup>a</sup>	5.8 ± 0.3 <sup>a</sup>	7.0 ± 0.2 <sup>a</sup>	7.4 ± 0.8 <sup>a</sup>
Post	1.3 ± 0.1	6.9 ± 0.4	3.2 ± 0.2	1.9 ± 0.1	1.6 ± 0.1
<i>p</i>	0.002*	0.001*	<0.001*	<0.001*	<0.001*
Δ (%)	6.2 ± 1.80	5.1 ± 1.43	-44.6 ± 5.2 <sup>abde</sup>	-72.1 ± 0.7 <sup>abce</sup>	-78.5 ± 3.4 <sup>abcd</sup>
LDL/HDL					
Pre	0.3 ± 0.0	2.9 ± 0.2	2.5 ± 0.1	3.1 ± 0.2	3.2 ± 0.2
Post	0.4 ± 0.0	3.2 ± 0.8	1.0 ± 0.1	0.6 ± 0.0	0.5 ± 0.0
<i>p</i>	0.003*	0.002*	<0.001*	<0.001*	<0.001*
Δ (%)	13.6 ± 4.3	7.9 ± 2.3 <sup>a</sup>	-57.4 ± 3.4 <sup>abde</sup>	-80.8 ± 1.3 <sup>abce</sup>	-84.7 ± 1.5 <sup>abcd</sup>
LDL/TC					
Pre	0.2 ± 0.0	0.5 ± 0.0	0.4 ± 0.0	0.4 ± 0.0	0.43 ± 0.0

Post	$0.3 \pm 0.0$	$0.4 \pm 0.0$	$0.3 \pm 0.0$	$0.3 \pm 0.0$	$0.31 \pm 0.0$
<i>p</i>	0.046*	0.008*	0.005*	<0.001*	<0.001*
$\Delta$ (%)	$0.5 \pm 5.1$	$2.6 \pm 1.2$	$-22.6 \pm 8.3^{abe}$	$-31.2 \pm 5.0^{ab}$	$-28.0 \pm 7.3^{ab}$

---

## Research Report

---

# *L. vannamei* shells reduces atherogenic index of plasma: A preclinical study in diabetic rats

Annisa Ayuningtyas<sup>a</sup>, Kis Djamiatun<sup>b</sup>, Tri Winarni Agustini<sup>c</sup> and Luthfia Dewi<sup>a,\*</sup>

<sup>a</sup>*Nutrition Department, Faculty of Nursing and Health Science, Universitas Muhammadiyah Semarang, Semarang, Indonesia*

<sup>b</sup>*Programme in Medical Education, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia*

<sup>c</sup>*Fish Product Technology, Faculty of Fisheries and Marine Science, Universitas Diponegoro, Semarang, Indonesia*

Received 1 June 2023

Accepted 16 August 2023

### Abstract.

**BACKGROUND:** Cardiovascular disease (CVD) appears to be the fundamental cause of morbidity and mortality in type 2 diabetes mellitus (T2DM). Improving the level of lipoprotein ratios using natural ingredients was widely used.

**OBJECTIVE:** This study aimed to examine antioxidant source-Litopenaeus vannamei shell powder (LVSP) to rebalance the lipoprotein ratios in diabetic rats.

**METHODS:** A-14 days prior to streptozotocin (STZ) injection, male Wistar rats ( $n=30$ ) were evenly grouped into non-intervention (C-), pre-intervention high-fat diet (C+), pre-intervention high-fat diet with LVSP dose 0.89 g/body weight (BW), pre-intervention high-fat diet with LVSP dose 1.77 g/BW (T2), and pre-intervention high-fat diet with astaxanthin 0.09 mg/BW (T3).

**RESULTS:** A reduction of LDL, total cholesterol (TC), and TC/HDL, LDL/HDL, and LDL/TC ratio was observed ( $p < 0.001$ ). A negative, strong correlation was found between the change of adiponectin to the change of TC ( $r=-0.94$ ), LDL ( $r=-0.92$ ), TC/HDL ( $r=-0.94$ ), LDL/HDL ( $r=-0.91$ ), and LDL/TC ( $r=-0.82$ ). The magnitude of improvement showed a dose-dependent manner, and the high dose delineated a comparable effect to astaxanthin.

**CONCLUSION:** The present study brought a profound finding on the potential of LV to reduce cardiovascular index in T2DM rats.

Keywords: Antioxidant, diabetes, lipid, lipoprotein ratio

---

\*Corresponding author: Luthfia Dewi, Nutrition Department, Faculty of Nursing and Health Science, Universitas Muhammadiyah Semarang, Semarang, Indonesia. Tel.: +62 24 76740296; Fax: 024 76740291; E-mail: luthfia@unimus.ac.id.



## 28 1. Introduction

29 People with T2DM have two to three folds higher morbidity and mortality caused by CVD, compared to those  
30 who have non-T2DM [1, 2]. T2DM per se causes qualitative, quantitatively, and kinetically abnormalities on  
31 the lipid profiles, thus leading to vascular complications [3, 4]. It has been concluded in a systematic review  
32 and meta-analysis that an increase in total cholesterol is a strong risk factor for coronary heart disease [5].  
33 Lipoproteins play a fundamental role as an intermediary of dietary lipid absorption and transportation from  
34 intestine into peripheral tissue and in reverse [6]. The question whether the changes of lipoprotein profiles  
35 contribute to cardiovascular disease has been well answered. A significant increase of LDL deposition in the  
36 plasma because of LDL catabolism disturbance triggered atherosclerosis in T2DM patients [7]. Additionally,  
37 lipoprotein ratios, also called atherogenic indices, are used to predict cardiovascular diseases in clinical practice  
38 [8–11].

39 Adiponectin, an adipokine secreted by adipose tissues, exerts as an insulin-sensitizing hormone and lipopro-  
40 tein protector [9]. Adiponectin receptors (Adipo R1 and Adipo R2) upregulate AMP-kinase activity, peroxisome  
41 proliferator-activated receptor (PPAR)  $\alpha$  ligand, and thus stimulate glucose uptake and lipid metabolism [12].  
42 Epidemiological studies reported that serum adiponectin negatively correlated with cardiovascular events [13,  
43 14]. The interplay of adiponectin in lipoprotein metabolism remains to be explored. The variety result of asso-  
44 ciation between circulating adiponectin and LDL among studies has been summarised in the published review  
45 [15].

46 Whiteleg or *vannamei* shrimp (*Litopenaeous vannamei*), is one of high-demand export commodities in Indone-  
47 sia, in the form of headless frozen shrimp. Approximately 40–45% of the body shrimp considered as by-product,  
48 including their shells [16]. The shrimp shells contain some beneficial nutrients, such as chitin (15%–40%),  
49 protein (20%–40%), calcium and magnesium carbonate (20%–50%), and other micronutrients such as astaxan-  
50 thin, lipids, and minerals [17]. Majority of pigments in crustacean shells is astaxanthin, representing 74–98%  
51 of total pigments [18]. To date, functional foods still become the main concern to manage the clinical con-  
52 ditions. For example, astaxanthin-extracted from shrimp shell improved the nephropathy in diabetic animals  
53 [19]. Whether the effect of shrimp shell powder to ameliorate lipoprotein profiles in diabetic condition yet to be  
54 determined.

55 The study inspecting whiteleg shrimp shell on reducing CVD risk in T2DM Wistar rats has been recently  
56 investigated [20]. Here, we further analysed the lipoprotein ratios after treated by LVSP. This study primarily  
57 aimed to examine the cardioprotective effect of *L. vannamei* shrimp shell powder (LVSP) in LDL, TC, and  
58 lipoprotein ratios. The secondary outcome of the present study was to correlate adiponectin changes with the  
59 biomarkers.

## 60 2. Materials and methods

### 61 2.1. Materials

62 *L. vannamei* shrimp shells were obtained from PT. Misaja Mitra, Tayu, Pati, Indonesia. The shells were  
63 cleaned from dirt and the remaining flesh using running water. Second, the clean shells were kept using a  
64 polyethylene bag in a freezer with the optimum temperature around  $-18^{\circ}\text{C}$  –  $(-10)^{\circ}\text{C}$  until were used. Before  
65 the shells being crushed using a food processor and sifted using the 60-mesh sieve, the shells were dried using  
66 freeze-drying method in Laboratorium Mikrobiologi PAU, Universitas Gajah Mada, Yogyakarta for 3–4 days  
67 ( $-40^{\circ}\text{C}$ ). The sifted LVSP was stored in a dark bottle coated with aluminium foil outside and an oxygen scav-  
68 enger inside and kept in a refrigerator at  $4^{\circ}\text{C}$ . Each bottle contained the ratio 1:1:1 of carapace: abdomen:  
69 thorax.




Fig. 1. Experimental protocol.

## 70 2.2. Study design and animals

71 The study protocol to assess the cardioprotective effect of LVSP in STZ-induced rats is shown in Fig. 1.  
 72 Male Wistar rats ( $n = 30$ ) were grouped into non-intervention (C-), pre-intervention high-fat diet (HFD) (C+),  
 73 pre-intervention HFD-STZ and intervened by LVSP dose 0.89 g/BW, pre-intervention HFD and intervened by  
 74 LVSP dose 1.77 g/BW (T2), and pre-intervention HFD and intervened by astaxanthin 0.09 mg/BW (T3) (AST;  
 75 ASTHIN<sup>®</sup> Force 4, SOHO, Indonesia). LVSP and AST were orally supplemented by gavage once a day in the  
 76 morning for 21 days. LVSP and AST diluted in 0.5% CMC-Na (Sigma-Aldrich, USA) till the solution became  
 77 homogeneous. C- and C+ groups received no treatment.

The rats were purchased and kept in single cage with a 12-h light/dark period at a temperature of  $20^{\circ}\text{C}\pm 1^{\circ}\text{C}$ , in *Laboratorium Hewan Coba*, PSPG UGM, Yogyakarta, Indonesia. This study has been extensively reviewed and approved by the ethics committee with No. 118/EC/H/FK-RSDK/X/2018).

### 2.3. Induction of T2DM

Four groups, C+, T1, T2, and T3 were induced T2DM in two phases: by HFD and streptozotocin (STZ). After seven days of acclimatization, HFD (15 g) was given to these four groups for 14 days. HFD-lard based diet composed which contained 100% fat (9 kcal/g). The standard diet contained 15% protein, 7% fat, and 78% carbohydrate (4.35 kcal/g). After HFD phase, the four groups were intraperitoneally injected by STZ (Nacalai Tesque, Kyoto, Japan) with dosage 45 mg/kg BW (diluted in a citrate buffer) and nicotinamide (NA; Nacalai Tesque, Kyoto, Japan) with dosage 110 mg/kg BW (diluted in a saline buffer). T2DM happened after three days of injection (data not shown). The determination of fasting blood glucose level of  $> 13.9$  mmol/L were considered to have T2DM condition [19].

### 2.4. Blood sampling

The plexus retro-orbital blood samples (approximately 3 mL) were taken twice during study period, after T2DM induction and at the end of the intervention. Before taken up the blood samples, the rats were fasted for 6–10 h. The blood then centrifuged at 4000 rpm for 15 min to separate serum and platelets. The serum was used to further analysis.

### 2.5. Biochemical markers determination

Total cholesterol levels were analysed by the CHOD-PAP method, which used principle of cholesterol determination after enzymatic hydrolysis and oxidation. The calorimetric indicator was quinoneimine, and it was generated from 4-aminoantipyrine and phenol by hydrogen peroxide under the catalytic action of peroxidase (Trinder's reaction). Determination of LDL levels was done by using CHOD PAP method and calculated from the combined results of total cholesterol, high density lipoprotein (HDL), and triglycerides (TG) using the Friedwald equation as follow:

$$\text{LDL} = \text{totalcholesterol} - \text{HDL} - \frac{\text{TG}}{5}$$

The data of HDL, TG and adiponectin levels have been published [21].

### 2.6. Statistical analysis

Shapiro–Wilk test was used to test the normality of data. The difference between pre- and post-treatments of all parameters was analysed by the paired *t*-test. The different among five groups of rats were analysed by one-way ANOVA followed by post-hoc Bonferroni. Correlations were evaluated using the Pearson correlation test. A significant different was set at level  $p < 0.05$ . All statistical analysis was proceeded using IBM SPSS Statistics 27.0 (IBM Corporation, Armonk, NY).




Fig. 2. Body weight (g) and food intake (g) starting from HFD-STZ phase (14 days) to the end of LVSP intervention. LVSP: *L. vannamei* shrimp shell powder. The data were presented as mean  $\pm$  SD. Pre- and post-analysis evaluated using paired *t*-test; the differences among five groups were analysed by one-way ANOVA followed by post-hoc Bonferroni;  $n = 25$  rats; \*significant ( $p < 0.05$ ).

### 103 3. Results

#### 104 3.1. Weight evolution and variation in food intake

105 The data from 25 rats were analysed in the present study since five animals died in the middle of experiment.  
 106 All data were normally distributed ( $p > 0.05$ ). This study is part of the study that has been published before [21],  
 107 and we used the adiponectin and HDL data to conduct the further analysis. The data of body weight (Fig. 2A)  
 108 and food intake (Fig. 2B) were obtained starting from STZ injection. The food intake of diabetic animals without  
 109 interventions (C+) increased by 32% ( $p < 0.05$ ) in week 3 with a progressive decline of body weight. The treatment  
 110 groups experienced a growing body weight the same trend as a C-. Furthermore, the group with the intervention  
 111 of high dose LVSP showed an increasing the average of food intake  $\sim 12\%$  ( $p < 0.05$ ) in week 3.

#### 112 3.2. Analysis of plasma atherogenic index

113 The LDL levels in C+, T1, T2, and T3 after T2DM induction increase significantly compared to C- (Table 1).  
 114 LVSP treatment markedly reduced LDL levels in T1 and T2 ( $p < 0.001$ ). The higher dose of LVSP showed a  
 115 better effect on reducing LDL after T2DM compared to the lower dose, showing a reduction was showed in  
 116 T2 group, from  $4.4 \pm 0.2$  to  $2.1 \pm 0.2$  mmol/L. The reduction in T2 ( $-52\%$ ) is similar with the effect of AST. A  
 117 significant increases of TC levels after T2DM induction was observed ( $p < 0.001$ ). Both low and high dose of

Table 1  
The effect of LVSP on LDL and TC levels, and lipoprotein ratios. The significance different outcomes were analysed from the change post to pre intervention.

	C-	C+	T1	T2	T3
LDL (mmol/L)					
Pre	1.5 ± 0.1	4.4 ± 0.2 <sup>a</sup>	4.0 ± 0.2 <sup>a</sup>	4.4 ± 0.2 <sup>a</sup>	4.3 ± 0.1 <sup>a</sup>
Post	1.6 ± 0.1	4.5 ± 0.2	2.8 ± 0.1	2.1 ± 0.2	1.9 ± 0.1
<i>p</i>	0.008*	0.004*	<0.001*	<0.001*	<0.001*
Δ (%)	9.8 ± 4.2	3.3 ± 1.3	-28.6 ± 4.8 <sup>abde</sup>	-52.3 ± 2.7 <sup>abc</sup>	-55.5 ± 3.5 <sup>abc</sup>
TC (mmol/L)					
Pre	5.4 ± 0.1	9.6 ± 0.3 <sup>a</sup>	9.4 ± 0.2 <sup>a</sup>	9.9 ± 0.3	9.8 ± 0.4
Post	5.5 ± 0.2	9.7 ± 0.3	8.7 ± 0.2	6.9 ± 0.2	6.1 ± 0.3
<i>p</i>	0.017*	0.001*	0.011*	<0.001*	<0.001*
Δ (%)	2.6 ± 1.5	0.7 ± 0.2	-7.4 ± 3.5 <sup>abde</sup>	-30.5 ± 2 <sup>abce</sup>	-37.9 ± 4.7 <sup>abcd</sup>
TC/HDL					
Pre	1.2 ± 0.0	6.6 ± 0.4 <sup>a</sup>	5.8 ± 0.3 <sup>a</sup>	7.0 ± 0.2 <sup>a</sup>	7.4 ± 0.8 <sup>a</sup>
Post	1.3 ± 0.1	6.9 ± 0.4	3.2 ± 0.2	1.9 ± 0.1	1.6 ± 0.1
<i>p</i>	0.002*	0.001*	<0.001*	<0.001*	<0.001*
Δ (%)	6.2 ± 1.80	5.1 ± 1.43	-44.6 ± 5.2 <sup>abde</sup>	-72.1 ± 0.7 <sup>abce</sup>	-78.5 ± 3.4 <sup>abcd</sup>
LDL/HDL					
Pre	0.3 ± 0.0	2.9 ± 0.2	2.5 ± 0.1	3.1 ± 0.2	3.2 ± 0.2
Post	0.4 ± 0.0	3.2 ± 0.8	1.0 ± 0.1	0.6 ± 0.0	0.5 ± 0.0
<i>p</i>	0.003*	0.002*	<0.001*	<0.001*	<0.001*
Δ (%)	13.6 ± 4.3	7.9 ± 2.3 <sup>a</sup>	-57.4 ± 3.4 <sup>abde</sup>	-80.8 ± 1.3 <sup>abce</sup>	-84.7 ± 1.5 <sup>abcd</sup>
LDL/TC					
Pre	0.2 ± 0.0	0.5 ± 0.0	0.4 ± 0.0	0.4 ± 0.0	0.43 ± 0.0
Post	0.3 ± 0.0	0.4 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	0.31 ± 0.0
<i>p</i>	0.046*	0.008*	0.005*	<0.001*	<0.001*
Δ (%)	0.5 ± 5.1	2.6 ± 1.2	-22.6 ± 8.3 <sup>abe</sup>	-31.2 ± 5.0 <sup>ab</sup>	-28.0 ± 7.3 <sup>ab</sup>

C-: non treatment group, C+: diabetic control group, T1: diabetic group and intervened by LVSP dose 0.89 g/BW, T2: diabetic group and intervened by LVSP dose 1.77 g/BW, T3: diabetic group and intervened by astaxanthin 0.09 mg/BW. LVSP: *L. vannamei* shrimp shell powder. The data were written as mean ± SD; *p* value between pre- and post- treatment were analysed using paired *t*-test. Δ (%): percent changes relative to pre-intervention. Differences among the groups were analysed using ANOVA followed by post-hoc Bonferroni. \*Represents a significant different between pre-post intervention. Alphabetical superscripts showed a significance level of <sup>a</sup>*p* < 0.05 compared to C-; <sup>b</sup>*p* < 0.05 compared to C+; <sup>c</sup>*p* < 0.05 compared to T1; <sup>d</sup>*p* < 0.05 compared to T2; <sup>e</sup>*p* < 0.05 compared to T3.

118 LVSP interventions attenuated total cholesterol by 7% and 30% respectively (*p* < 0.001). LVSP with high dose  
 119 showed a comparable lowering-effect with AST intervention (*p* > 0.05). Lipoprotein ratios in the present study  
 120 were indicated by TC-HDL, LDL-HDL, and LDL-TC ratio. Low and high dose of LVSP significantly decreased  
 121 the ratio of TC-HDL by 45% and 72%, LDL-HDL by 57 and 80%, and LDL-TC by 22 and 31% (*p* < 0.05). LVSP  
 122 with high dosage exerted a comparable effect as AST.

### 123 3.3. Adiponectin – plasma atherogenic index association

124 A coefficient of determination in all biomarkers with adiponectin was shown in Fig. 3A–F. By providing LVSP,  
 125 the change of total cholesterol levels influenced approximately 72% (*p* < 0.05) of the change adiponectin levels.




Fig. 3. (Continued)

Fig. 3. Correlation between the changes of adiponectin and TC (A), LDL (B), LDL/HDL ratio (C), LDL/TC ratio, TC/HDL ratio (E), and food intake (F). The correlation was taken from the data of groups intervened by LVSP ( $n=20$ ). The change of value was calculated from the beginning of intervention to the end of intervention. LVSP: *L. vannamei* shrimp shell powder.  $R^2$ : coefficient of determination. Correlation tests were taken using Pearson correlation test.

---

126 Furthermore, the linear interaction in the groups intervened by LVSP between the decreasing LDL/HDL ratio  
127 and increasing adiponectin was shown an approximate 62% ( $p<0.05$ ). A negative correlation was also shown  
128 by the change of TC/HDL ratio to the change adiponectin, which approximately 68% ( $p<0.05$ ) an increasing  
129 adiponectin was determined by TC/HDL ratio.

#### 130 4. Discussion

131 To our knowledge, the present study provides the further analysis to confirm the effect of shrimp shells that is  
132 considered as by-product to alleviate cardiovascular disease risk in T2DM [20]. Here, we summarised the findings  
133 as follows: (1) LVSP treatment maintained the body weight in diabetic condition; (2) LVSP improved lipid  
134 profiles; (3) LVSP decreased lipoprotein ratios; (4) negative correlation between adiponectin and all biomarkers  
135 was observed.

136 In the previous study using animal model, the injection of STZ changed body composition, including body  
137 size, which is mimicking people with T2DM [22]. In the present study, a significant dropped of body weight was  
138 shown in the diabetic group without intervention which is likely associated with the impairment of muscle and  
139 splanchnic cells to uptake glucose [23]. We found that LVSP has a capability to sustain the growth in diabetic  
140 state similar with the non-diabetic condition. The body weight data in this study support our previous work,  
141 showing that both of LVSP treatments increased insulin sensitivity, indicated by decreasing the ratio of TG-HDL  
142 [21].

143 The abnormality of lipid profiles in T2DM has been documented in epidemiological studies [24, 25]. In this  
144 animal study, diabetic condition increased the proportion of LDL to total cholesterol about 45%, delineating  
145 28% higher compared to non-diabetic group. The LDL increased by 197% in diabetic group after being exposed  
146 by HFD-lard based diet and STZ due to the impairment of insulin sensitivity [21] that affected the function  
147 of LDL-receptor [26]. That LVSP intervention markedly reduced the LDL levels hypothesised the bioactive  
148 components in LVSP (including astaxanthin) exerts as a hypolipidemic agent in diabetic animals. This result  
149 robust the recently published paper that LVSP attenuated dyslipidaemia in diabetic state [20].

150 The ratio of lipoproteins showed a better prediction on CVD risk compared to conventional lipid levels [27,  
151 28]. Dietary fat has been known to stimulate lipid abnormalities in animal study [29]. In the present study, we  
152 found that the increasing of TC/HDL ratio and LDL/HDL ratio in non-diabetic control group due to the raising  
153 total cholesterol and LDL levels was mediated by total energy intake. This may infer the amount of energy  
154 intake more affecting to raise total cholesterol and LDL levels rather than fat content. Of note, in the certain  
155 levels, total cholesterol is required for constructing cell membrane [30]. The increasing LVSP lowered the ratio  
156 of TC-HDL, LDL-HDL, and LDL-TC in dose-dependent levels and the magnitude of ratio reduction in the  
157 high dose LVSP group came approach to astaxanthin supplement. These pre-clinical results provided the future  
158 research of generating powder-based supplement of LVSP. As expected, the predictors of CVD in the presents  
159 study were all negatively strong correlation with adiponectin levels. The mechanism underlined the correlations  
160 between adiponectin and lipoprotein ratios remains to be elucidated. We hypothesize the association is mediated  
161 by increasing HDL and decreasing TG [15, 21].

162 The effect of shrimp shell on the change of adiponectin levels [21] and the lipid profiles has been reported  
163 before [20]. Of note, the method of shrimp shell processing in the current study was different with the previous

164 report [20], therefore, the effect of shrimp shell in the powder form may result the different outcomes. Here, we  
165 add the additional insight that decreasing total cholesterol, TC/HDL ratio, and LDL/HDL ratio are correlated  
166 with increasing adiponectin levels. However, we unable to fully delineate the causal relationship among the  
167 parameters. Since adiponectin has critical role for endothelium-dependent vasodilation [25], it would be interest  
168 to examine whether lipid profiles have a direct impact on adiponectin levels.

169 As social animals, a single cage might promote stress for rats [31]. Since we prioritized to measure the amount  
170 of food intake of every single rat, we put the animals in the single house. Furthermore, the male rodents were  
171 prone to fighting, thus we separated the animal in individual house during the intervention periods. Five animals  
172 could not survive up to the sacrifice day, which was caused by very low food intake and therefore their body  
173 weight was shrinkage. Furthermore, a significant increase on the atherogenic index in the C- groups implied the  
174 progress of atherosclerosis in the normal weight *in vivo* is also influenced by physical activity. This fundamental  
175 finding robust the existing observational study in human [32].

176 In summary, LVSP alleviated the risk of CVD by decreasing LDL, TC, TC/HDL, LDL/HDL, and LDL/TC in  
177 T2DM-induced Wistar rats. A high dose of LVSP 1.77 g/BW showed a comparable effect as AST. Whether the  
178 higher dose is more beneficial for lipid profiles in diabetic state requires more animal studies. The present study  
179 provided the hypolipidemic effect on T2DM that is possible to apply in the human study.

## 180 Acknowledgments

181 The authors thank the laboratory technicians for their participation.

## 182 Funding statement

183 The authors report no funding.

## 184 Conflict of interest

185 There is no conflict of interest declared.

## 186 Authors' contributions

187 Dewi, L: conceptualization, methodology, software. Ayuningtyas, A: data curation, writing-original draft  
188 preparation. Dewi, L: visualization, investigation. Djamiatun, K: supervision, Agustini, TW: supervision, Ayun-  
189 ingyas, A: software, validation. Dewi, L: writing-reviewing and editing.

## 190 References

- 191 [1] Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have  
192 all risk factors the same strength? *World J Diabetes*. 2014;5(4):444-70. doi: 10.4239/wjd.v5.i4.444
- 193 [2] Schmidt AM. Diabetes mellitus and cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 2019;39(4):558-68. doi:  
194 10.1161/atvbaha.119.310961
- 195 [3] Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: an overview of global  
196 trends of macro and micro vascular complications. *Eur J Prev Cardiol*. 2019;26(2\_suppl):25-32. doi: 10.1177/2047487319878371



- 197 [4] Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? *Diabetologia*. 2015;58(5):886-99. doi: 10.1007/s00125-015-  
198 3525-8
- 199 [5] Peters SA, Singhathe Y, Mackay D, Huxley RR, Woodward M. Total cholesterol as a risk factor for coronary heart dis-  
200 ease and stroke in women compared with men: a systematic review and meta-analysis. *Atherosclerosis*. 2016;248:123-31. doi:  
201 10.1016/j.atherosclerosis.2016.03.016
- 202 [6] Ginsberg HN. Lipoprotein physiology. *Endocrinol Metab Clin North Am*. 1998;27(3):503-19. doi: 10.1016/s0889-8529(05)70023-2
- 203 [7] Yadav NK, Thanpari C, Shrewastwa MK, Mittal RK. Comparison of lipid profile in type-2 obese diabetics and obese non-  
204 diabetic individuals. a hospital based study from Western Nepal. *Kathmandu Univ Med J (KUMJ)*. 2012;10(39):44-7. doi:  
205 10.3126/kumj.v10i3.8017
- 206 [8] Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, et al. Lipoprotein ratios: physiological significance and clinical  
207 usefulness in cardiovascular prevention. *Vasc Health Risk Manag*. 2009;5:757-65. doi.
- 208 [9] Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH. LDL-C/HDL-C ratio in subjects with cardiovascular  
209 disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport)  
210 study. *Curr Med Res Opin*. 2005;21(11):1865-74. doi: 10.1185/030079905x74952
- 211 [10] Panagiotakos DB, Pitsavos C, Skoumas J, Chrysohoou C, Toutouza M, Stefanadis CI, et al. Importance of LDL/HDL cholesterol ratio  
212 as a predictor for coronary heart disease events in patients with heterozygous familial hypercholesterolaemia: a 15-year follow-up  
213 (1987–2002). *Curr Med Res Opin*. 2003;19(2):89-94. doi.
- 214 [11] Quispe R, Elshazly MB, Zhao D, Toth PP, Puri R, Virani SS, et al. Total cholesterol/HDL-cholesterol ratio discordance with LDL-  
215 cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study.  
216 *Eur J Prev Cardiol*. 2020;27(15):1597-605. doi: 10.1177/2047487319862401.
- 217 [12] Caselli C. Role of adiponectin system in insulin resistance. *Mol Genet Metab*. 2014;113(3):155-60. doi: 10.1016/j.ymgme.2014.09.003.
- 218 [13] Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius Br. Serum adiponectin Is a predictor of coronary heart disease: a  
219 population-based 10-year follow-up study in elderly men. *J Clin Endocrinol Metab*. 2007;92(2):571-6. doi: 10.1210/jc.2006-1067
- 220 [14] Koenig W, Khuseynova N, Baumert J, Meisinger C, Löwel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus  
221 and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern  
222 Germany. *J Am Coll Cardiol*. 2006;48(7):1369-77. doi: 10.1016/j.jacc.2006.06.053
- 223 [15] Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism. *Obes Rev*. 2013;14(12):939-49. doi: 10.1111/obr.12064
- 224 [16] Vázquez JA, Ramos P, Mirón J, Valcarcel J, Sotelo CG, Pérez-Martín RI. Production of chitin from *Penaeus vannamei* by-products to  
225 pilot plant scale using a combination of enzymatic and chemical processes and subsequent optimization of the chemical production  
226 of chitosan by response surface methodology. *Mar Drugs*. 2017;15(6). doi: 10.3390/md15060180
- 227 [17] Khoushab F, Yamabhai M. Chitin research revisited. *Mar Drugs*. 2010;8(7):1988-2012. doi: 10.3390/md8071988
- 228 [18] Shahidi F, Metusalach, Brown JA. Carotenoid pigments in seafoods and aquaculture. *Crit Rev Food Sci Nutr*. 1998;38(1):1-67. doi:  
229 10.1080/10408699891274165
- 230 [19] Sila A, Ghilissi Z, Kamoun Z, Makni M, Nasri M, Bougataf A, et al. Astaxanthin from shrimp by-products ameliorates nephropathy  
231 in diabetic rats. *Eur J Nutr*. 2015;54(2):301-7. doi: 10.1007/s00394-014-0711-2
- 232 [20] Huang CH, Lin CH, Huang HH, Tsai GJ. Development of fermented shrimp shell product with hypoglycemic and hypolipidemic  
233 effects on diabetic rats. *Metabolites*. 2022;12(8). doi: 10.3390/metabo12080695
- 234 [21] Ayuningtyas A, Agustini TW, Djamiatun K. Whiteleg shrimp shell powder ameliorates adiponectin and triglyceride-to-HDL ratio in  
235 type 2 diabetic rats. *NFS*. 2020;50(4):617-29. doi: 10.1108/NFS-04-2019-0138
- 236 [22] Lin YH, Tsai SC, Chuang SJ, Harris MB, Masodsai K, Chen PN, et al. Whole-life body composition trajectory and longevity: role of  
237 insulin. *Aging (Albany NY)*. 2021;13(7):9719-31. doi: 10.18632/aging.202727
- 238 [23] Basu A, Basu R, Shah P, Vella A, Johnson CM, Jensen M, et al. Type 2 diabetes impairs splanchnic uptake of glucose but does not  
239 alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity.  
240 *Diabetes*. 2001;50(6):1351-62. doi: 10.2337/diabetes.50.6.1351
- 241 [24] Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. *Lipids Health*  
242 *Dis*. 2014;13:183. doi: 10.1186/1476-511x-13-183
- 243 [25] Antwi-Baffour S, Kyeremeh R, Boateng SO, Annison L, Seidu MA. Haematological parameters and lipid profile abnormalities among  
244 patients with type-2 diabetes mellitus in Ghana. *Lipids Health Dis*. 2018;17(1):283. doi: 10.1186/s12944-018-0926-y
- 245 [26] Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. *Diabetes Care*. 1991;14(9):839-  
246 55. doi: 10.2337/diacare.14.9.839
- 247 [27] Zhu L, Lu Z, Zhu L, Ouyang X, Yang Y, He W, et al. Lipoprotein ratios are better than conventional lipid parameters in predicting  
248 coronary heart disease in Chinese Han people. *Kardiol Pol*. 2015;73(10):931-8. doi: 10.5603/KP.a2015.0086
- 249 [28] Barzi F, Patel A, Woodward M, Lawes CM, Ohkubo T, Gu D, et al. A comparison of lipid variables as predictors of cardiovascular  
250 disease in the Asia Pacific region. *Ann Epidemiol*. 2005;15(5):405-13. doi: 10.1016/j.annepidem.2005.01.005

- 251 [29] Chen B, Huang Y, Zheng D, Ni R, Bernards MA. Dietary fatty acids alter lipid profiles and induce myocardial dysfunction without  
252 causing metabolic disorders in mice. *Nutrients*. 2018;10(1). doi: 10.3390/nu10010106
- 253 [30] Krause MR, Regen SL. The structural role of cholesterol in cell membranes: from condensed bilayers to lipid rafts. *Acc Chem Res*.  
254 2014;47(12):3512-21. doi: 10.1021/ar500260t
- 255 [31] Manouze H, Ghestem A, Poillerat V, Bennis M, Ba-M'hamed S, Benoliel JJ, et al. Effects of single cage housing on stress, cognitive,  
256 and seizure parameters in the rat and mouse pilocarpine models of epilepsy. *eNeuro*. 2019;6(4). doi: 10.1523/eneuro.0179-18.2019
- 257 [32] Crichton GE, Alkerwi A. Physical activity, sedentary behavior time and lipid levels in the Observation of Cardiovascular Risk Factors  
258 in Luxembourg study. *Lipids Health Dis*. 2015;14:87. doi: 10.1186/s12944-015-0085-3

Uncorrected Author Proof

# Point-to-point Response

1 Point-to-point response:

2 Reviewer #1:

3

4 1. In the title, you said that LVSP reduces cardiovascular risk factors.  
5 However, you only analyzed the atherogenic index of plasma. Analysis of  
6 cardiovascular risk factors requires analysis of other markers such as CKMB,  
7 troponin, homocysteine, CRP....

8 **Response:** *this research only analyzes the atherogenic index of plasma as a*  
9 *risk factor for cardiovascular disease. We have no data about CKMB,*  
10 *troponin, homocysteine, and CRP, so we mentioned it as the limitation of our*  
11 *study.*

12

13 2. In section 2.6. Statistical analysis, only the tests effectively carried out in  
14 this work should be mentioned, especially as you have stated in the results  
15 that all the data have a normal distribution (non-parametric tests should not be  
16 mentioned).

17 **Response:** *already revised on the paper*

18

19 3. The results section is not well organized, and the data are not sufficiently  
20 exploited. The results section should be divided into 3 sections, with more  
21 analysis and comparison:

- 22 1. Weight evolution and variation in food intake.
- 23 2. Analysis of plasma atherogenic index.
- 24 3. Adiponectin - plasma atherogenic index association.

25 **Response:** *already revised on the paper*

26

27 4. How do you explain the presence of significant differences in all parameters  
28 analyzed between Pre and Post in group C-?

29 **Response:** *the significant differences between pre and post in C- group*  
30 *showed an adverse trend with the treatment group for all parameters. It is*  
31 *inline with the theory that diabetes may worsen the lipid parameters and the*  
32 *atherogenic index. It's already mentioned in the article*

33

34 5. In the ANOVA and correlation tests, why did you use the percentages of  
35 Pre-Post variations and not the absolute values in Post?

36 **Response:**

37 *We justify that the relative number make the reader easier to interpret the*  
38 *data*

39

40 6. Why didn't you carry out a correlation study in the C+ and T3 (astaxanthin)  
41 groups for a better comparison?

42 **Response:**

43

44 7. Concerning weight evolution (Fig. 2A), it is interesting to plot the curves  
45 since the beginning of the experiment (start of HFD administration).

46 **Response:**

47

48 8. In Figs. 2 and 3, the statistical tests used and the numbers of rats are not  
49 mentioned.

50 **Response:** *already revised as a note for the figures*

51

52



# Revision Confirmation

Luthfia Dewi <luthfia@unimus.ac.id>

---

## Submission Confirmation for MNM-230048R1

1 message

---

**Mediterranean Journal of Nutrition and Metabolism** <em@editorialmanager.com>  
Reply-To: Mediterranean Journal of Nutrition and Metabolism <editorial@iospress.nl>  
To: Luthfia Dewi <luthfia@unimus.ac.id>

Mon, Jul 24, 2023 at 2:00 PM

Ref.: Ms. No. MNM-230048R1

L. vannamei shells reduces atherogenic index of plasma: A preclinical study in diabetic rats

Dear Dr. Dewi,

Mediterranean Journal of Nutrition and Metabolism has received your revised submission.

You may check the status of your manuscript by logging onto Editorial Manager at (<https://www.editorialmanager.com/mnm/>).

Kind regards,

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/mnm/login.asp?a=r>). Please contact the publication office if you have any questions.



# Final Proof

Luthfia Dewi <luthfia@unimus.ac.id>

---

## Corrected Proof of manuscript - MNM230048

3 messages

---

**Corr IOS** <corr.ios@thomsondigital.com>  
To: "luthfia@unimus.ac.id" <luthfia@unimus.ac.id>

Tue, Sep 12, 2023 at 1:34 AM

Dear Luthfia Dewi,

Enclosed herewith is the corrected and final proof of your article.

In this corrected proof all your corrections have been included. Kindly check if all corrections that you have marked on the first proofs have been correctly implemented. If any of your corrections have been misinterpreted and/or have been carried out incorrectly then please let us know at your earliest convenience.

No further proof will be sent from this stage onwards and final corrections will be visible in the published version. You will receive an Author's Copy of the published pdf by email on publication of the issue to which your article has been assigned.

This corrected Pre-print proof will replace your uncorrected proof in our contents section online.

Sincerely,

Thomson Digital / for IOS Press

Disclaimer: The contents of this e-mail and any attachment(s) are confidential and intended for the named recipient(s) only. It shall not attach any liability on the originator or Thomson Digital or its affiliates. Any views or opinions presented in this email are solely those of the author and may not necessarily reflect the opinions of Thomson Digital or its affiliates. Any form of reproduction, dissemination, copying, disclosure, modification, distribution and / or publication of this message without the prior written consent of the author of this e-mail is strictly prohibited. If you have received this email in error, please delete it and notify the sender immediately.

---

### 2 attachments

 **MNM230048.pdf**  
1226K

 **Author Query Form\_MNM230048.docx**  
72K

---

**Luthfia Dewi** <luthfia@unimus.ac.id>  
To: Corr IOS <corr.ios@thomsondigital.com>

Tue, Sep 12, 2023 at 6:35 AM

Dear Thomson Digital,  
Yes, everything is correct.

[Quoted text hidden]

---

**Corr IOS** <corr.ios@thomsondigital.com>  
To: Luthfia Dewi <luthfia@unimus.ac.id>

Tue, Sep 12, 2023 at 2:11 PM

Dear Author,

Thank you for your review and response.

Regards,

Bharathi

[Quoted text hidden]

[Quoted text hidden]

## Research Report

---

# *L. vannamei* shells reduces atherogenic index of plasma: A preclinical study in diabetic rats

Rr. Annisa Ayuningtyas<sup>a</sup>, Kis Djamiatun<sup>b</sup>, Tri Winarni Agustini<sup>c</sup> and Luthfia Dewi<sup>a,\*</sup>

<sup>a</sup>Nutrition Department, Faculty of Nursing and Health Science, Universitas Muhammadiyah Semarang, Semarang, Indonesia

<sup>b</sup>Programme in Medical Education, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

<sup>c</sup>Fish Product Technology, Faculty of Fisheries and Marine Science, Universitas Diponegoro, Semarang, Indonesia

Received 1 June 2023

Accepted 16 August 2023

Pre-press 7 September 2023

Published 11 December 2023

### Abstract.

**BACKGROUND:** Cardiovascular disease (CVD) appears to be the fundamental cause of morbidity and mortality in type 2 diabetes mellitus (T2DM). Improving the level of lipoprotein ratios using natural ingredients was widely used.

**OBJECTIVE:** This study aimed to examine antioxidant source-Litopenaeus vannamei shell powder (LVSP) to rebalance the lipoprotein ratios in diabetic rats.

**METHODS:** A-14 days prior to streptozotocin (STZ) injection, male Wistar rats ( $n=30$ ) were evenly grouped into non-intervention (C-), pre-intervention high-fat diet (C+), pre-intervention high-fat diet with LVSP dose 0.89 g/body weight (BW), pre-intervention high-fat diet with LVSP dose 1.77 g/BW (T2), and pre-intervention high-fat diet with astaxanthin 0.09 mg/BW (T3).

**RESULTS:** A reduction of LDL, total cholesterol (TC), and TC/HDL, LDL/HDL, and LDL/TC ratio was observed ( $p<0.001$ ). A negative, strong correlation was found between the change of adiponectin to the change of TC ( $r=-0.94$ ), LDL ( $r=-0.92$ ), TC/HDL ( $r=-0.94$ ), LDL/HDL ( $r=-0.91$ ), and LDL/TC ( $r=-0.82$ ). The magnitude of improvement showed a dose-dependent manner, and the high dose delineated a comparable effect to astaxanthin.

**CONCLUSION:** The present study brought a profound finding on the potential of LV to reduce cardiovascular index in T2DM rats.

Keywords: Antioxidant, diabetes, lipid, lipoprotein ratio

---

\*Corresponding author: Luthfia Dewi, Nutrition Department, Faculty of Nursing and Health Science, Universitas Muhammadiyah Semarang, Semarang, Indonesia. Tel.: +62 24 76740296; Fax: 024 76740291; E-mail: luthfia@unimus.ac.id.



## 1. Introduction

People with T2DM have two to three folds higher morbidity and mortality caused by CVD, compared to those who have non-T2DM [1, 2]. T2DM per se causes qualitative, quantitative, and kinetic abnormalities on the lipid profiles, thus leading to vascular complications [3, 4]. It has been concluded in a systematic review and meta-analysis that an increase in total cholesterol is a strong risk factor for coronary heart disease [5]. Lipoproteins play a fundamental role as an intermediary of dietary lipid absorption and transportation from intestine into peripheral tissue and in reverse [6]. The question whether the changes of lipoprotein profiles contribute to cardiovascular disease has been well answered. A significant increase of LDL deposition in the plasma because of LDL catabolism disturbance triggered atherosclerosis in T2DM patients [7]. Additionally, lipoprotein ratios, also called atherogenic indices, are used to predict cardiovascular diseases in clinical practice [8–11].

Adiponectin, an adipokine secreted by adipose tissues, exerts as an insulin-sensitizing hormone and lipoprotein protector [9]. Adiponectin receptors (Adipo R1 and Adipo R2) upregulate AMP-kinase activity, *peroxisome proliferator-activated receptor* (PPAR)  $\alpha$  ligand, and thus stimulate glucose uptake and lipid metabolism [12]. Epidemiological studies reported that serum adiponectin negatively correlated with cardiovascular events [13, 14]. The interplay of adiponectin in lipoprotein metabolism remains to be explored. The variety result of association between circulating adiponectin and LDL among studies has been summarised in the published review [15].

Whiteleg or *vannamei* shrimp (*Litopenaeous vannamei*), is one of high-demand export commodities in Indonesia, in the form of headless frozen shrimp. Approximately 40–45% of the body shrimp considered as by-product, including their shells [16]. The shrimp shells contain some beneficial nutrients, such as chitin (15%–40%), protein (20%–40%), calcium and magnesium carbonate (20%–50%), and other micronutrients such as astaxanthin, lipids, and minerals [17]. Majority of pigments in crustacean shells is astaxanthin, representing 74–98% of total pigments [18]. To date, functional foods still become the main concern to manage the clinical conditions. For example, astaxanthin-extracted from shrimp shell improved the nephropathy in diabetic animals [19]. Whether the effect of shrimp shell powder to ameliorate lipoprotein profiles in diabetic condition yet to be determined.

The study inspecting whiteleg shrimp shell on reducing CVD risk in T2DM Wistar rats has been recently investigated [20]. Here, we further analysed the lipoprotein ratios after treated by LVSP. This study primarily aimed to examine the cardioprotective effect of *L. vannamei* shrimp shell powder (LVSP) in LDL, TC, and lipoprotein ratios. The secondary outcome of the present study was to correlate adiponectin changes with the biomarkers.

## 2. Materials and methods

### 2.1. Materials

*L. vannamei* shrimp shells were obtained from PT. Misaja Mitra, Tayu, Pati, Indonesia. The shells were cleaned from dirt and the remaining flesh using running water. Second, the clean shells were kept using a polyethylene bag in a freezer with the optimum temperature around  $-18^{\circ}\text{C}$  –  $(-10)^{\circ}\text{C}$  until were used. Before the shells being crushed using a food processor and sifted using the 60-mesh sieve, the shells were dried using freeze-drying method in Laboratorium Mikrobiologi PAU, Universitas Gajah Mada, Yogyakarta for 3–4 days ( $-40^{\circ}\text{C}$ ). The sifted LVSP was stored in a dark bottle coated with aluminium foil outside and an oxygen scavenger inside and kept in a refrigerator at  $4^{\circ}\text{C}$ . Each bottle contained the ratio 1:1:1 of carapace: abdomen: thorax.




Fig. 1. Experimental protocol.

## 2.2. Study design and animals

The study protocol to assess the cardioprotective effect of LVSP in STZ-induced rats is shown in Fig. 1. Male Wistar rats ( $n = 30$ ) were grouped into non-intervention (C-), pre-intervention high-fat diet (HFD) (C+), pre-intervention HFD-STZ and intervened by LVSP dose 0.89 g/BW, pre-intervention HFD and intervened by LVSP dose 1.77 g/BW (T2), and pre-intervention HFD and intervened by astaxanthin 0.09 mg/BW (T3) (AST; ASTHIN<sup>®</sup> Force 4, SOHO, Indonesia). LVSP and AST were orally supplemented by gavage once a day in the morning for 21 days. LVSP and AST diluted in 0.5% CMC-Na (Sigma-Aldrich, USA) till the solution became homogeneous. C- and C+ groups received no treatment.

The rats were purchased and kept in single cage with a 12-h light/dark period at a temperature of  $20^{\circ}\text{C}\pm 1^{\circ}\text{C}$ , in *Laboratorium Hewan Coba*, PSPG UGM, Yogyakarta, Indonesia. This study has been extensively reviewed and approved by the ethics committee with No. 118/EC/H/FK-RSDK/X/2018).

### 2.3. Induction of T2DM

Four groups, C+, T1, T2, and T3 were induced T2DM in two phases: by HFD and streptozotocin (STZ). After seven days of acclimatization, HFD (15 g) was given to these four groups for 14 days. HFD-lard based diet composed which contained 100% fat (9 kcal/g). The standard diet contained 15% protein, 7% fat, and 78% carbohydrate (4.35 kcal/g). After HFD phase, the four groups were intraperitoneally injected by STZ (Nacalai Tesque, Kyoto, Japan) with dosage 45 mg/kg BW (diluted in a citrate buffer) and nicotinamide (NA; Nacalai Tesque, Kyoto, Japan) with dosage 110 mg/kg BW (diluted in a saline buffer). T2DM happened after three days of injection (data not shown). The determination of fasting blood glucose level of  $> 13.9$  mmol/L were considered to have T2DM condition [19].

### 2.4. Blood sampling

The plexus retro-orbital blood samples (approximately 3 mL) were taken twice during study period, after T2DM induction and at the end of the intervention. Before taken up the blood samples, the rats were fasted for 6–10 h. The blood then centrifuged at 4000 rpm for 15 min to separate serum and platelets. The serum was used to further analysis.

### 2.5. Biochemical markers determination

Total cholesterol levels were analysed by the CHOD-PAP method, which used principle of cholesterol determination after enzymatic hydrolysis and oxidation. The calorimetric indicator was quinoneimine, and it was generated from 4-aminoantipyrine and phenol by hydrogen peroxide under the catalytic action of peroxidase (Trinder's reaction). Determination of LDL levels was done by using CHOD PAP method and calculated from the combined results of total cholesterol, high density lipoprotein (HDL), and triglycerides (TG) using the Friedwald equation as follow:

$$\text{LDL} = \text{totalcholesterol} - \text{HDL} - \frac{\text{TG}}{5}$$

The data of HDL, TG and adiponectin levels have been published [21].

### 2.6. Statistical analysis

Shapiro–Wilk test was used to test the normality of data. The difference between pre- and post-treatments of all parameters was analysed by the paired *t*-test. The different among five groups of rats were analysed by one-way ANOVA followed by post-hoc Bonferroni. Correlations were evaluated using the Pearson correlation test. A significant different was set at level  $p < 0.05$ . All statistical analysis was proceeded using IBM SPSS Statistics 27.0 (IBM Corporation, Armonk, NY).




Fig. 2. Body weight (g) and food intake (g) starting from HFD-STZ phase (14 days) to the end of LVSP intervention. LVSP: *L. vannamei* shrimp shell powder. The data were presented as mean  $\pm$  SD. Pre- and post-analysis evaluated using paired *t*-test; the differences among five groups were analysed by one-way ANOVA followed by post-hoc Bonferroni;  $n = 25$  rats; \*significant ( $p < 0.05$ ).

### 3. Results

#### 3.1. Weight evolution and variation in food intake

The data from 25 rats were analysed in the present study since five animals died in the middle of experiment. All data were normally distributed ( $p > 0.05$ ). This study is part of the study that has been published before [21], and we used the adiponectin and HDL data to conduct the further analysis. The data of body weight (Fig. 2A) and food intake (Fig. 2B) were obtained starting from STZ injection. The food intake of diabetic animals without interventions (C+) increased by 32% ( $p < 0.05$ ) in week 3 with a progressive decline of body weight. The treatment groups experienced a growing body weight the same trend as a C-. Furthermore, the group with the intervention of high dose LVSP showed an increasing the average of food intake  $\sim 12\%$  ( $p < 0.05$ ) in week 3.

#### 3.2. Analysis of plasma atherogenic index

The LDL levels in C+, T1, T2, and T3 after T2DM induction increase significantly compared to C- (Table 1). LVSP treatment markedly reduced LDL levels in T1 and T2 ( $p < 0.001$ ). The higher dose of LVSP showed a better effect on reducing LDL after T2DM compared to the lower dose, showing a reduction was showed in T2 group, from  $4.4 \pm 0.2$  to  $2.1 \pm 0.2$  mmol/L. The reduction in T2 ( $-52\%$ ) is similar with the effect of AST. A significant increases of TC levels after T2DM induction was observed ( $p < 0.001$ ). Both low and high dose of

Table 1  
The effect of LVSP on LDL and TC levels, and lipoprotein ratios. The significance different outcomes were analysed from the change post to pre intervention.

	C-	C+	T1	T2	T3
LDL (mmol/L)					
Pre	1.5 ± 0.1	4.4 ± 0.2 <sup>a</sup>	4.0 ± 0.2 <sup>a</sup>	4.4 ± 0.2 <sup>a</sup>	4.3 ± 0.1 <sup>a</sup>
Post	1.6 ± 0.1	4.5 ± 0.2	2.8 ± 0.1	2.1 ± 0.2	1.9 ± 0.1
<i>p</i>	0.008*	0.004*	<0.001*	<0.001*	<0.001*
Δ (%)	9.8 ± 4.2	3.3 ± 1.3	-28.6 ± 4.8 <sup>abde</sup>	-52.3 ± 2.7 <sup>abc</sup>	-55.5 ± 3.5 <sup>abcd</sup>
TC (mmol/L)					
Pre	5.4 ± 0.1	9.6 ± 0.3 <sup>a</sup>	9.4 ± 0.2 <sup>a</sup>	9.9 ± 0.3	9.8 ± 0.4
Post	5.5 ± 0.2	9.7 ± 0.3	8.7 ± 0.2	6.9 ± 0.2	6.1 ± 0.3
<i>p</i>	0.017*	0.001*	0.011*	<0.001*	<0.001*
Δ (%)	2.6 ± 1.5	0.7 ± 0.2	-7.4 ± 3.5 <sup>abde</sup>	-30.5 ± 2 <sup>abce</sup>	-37.9 ± 4.7 <sup>abcd</sup>
TC/HDL					
Pre	1.2 ± 0.0	6.6 ± 0.4 <sup>a</sup>	5.8 ± 0.3 <sup>a</sup>	7.0 ± 0.2 <sup>a</sup>	7.4 ± 0.8 <sup>a</sup>
Post	1.3 ± 0.1	6.9 ± 0.4	3.2 ± 0.2	1.9 ± 0.1	1.6 ± 0.1
<i>p</i>	0.002*	0.001*	<0.001*	<0.001*	<0.001*
Δ (%)	6.2 ± 1.80	5.1 ± 1.43	-44.6 ± 5.2 <sup>abde</sup>	-72.1 ± 0.7 <sup>abce</sup>	-78.5 ± 3.4 <sup>abcd</sup>
LDL/HDL					
Pre	0.3 ± 0.0	2.9 ± 0.2	2.5 ± 0.1	3.1 ± 0.2	3.2 ± 0.2
Post	0.4 ± 0.0	3.2 ± 0.8	1.0 ± 0.1	0.6 ± 0.0	0.5 ± 0.0
<i>p</i>	0.003*	0.002*	<0.001*	<0.001*	<0.001*
Δ (%)	13.6 ± 4.3	7.9 ± 2.3 <sup>a</sup>	-57.4 ± 3.4 <sup>abde</sup>	-80.8 ± 1.3 <sup>abce</sup>	-84.7 ± 1.5 <sup>abcd</sup>
LDL/TC					
Pre	0.2 ± 0.0	0.5 ± 0.0	0.4 ± 0.0	0.4 ± 0.0	0.43 ± 0.0
Post	0.3 ± 0.0	0.4 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	0.31 ± 0.0
<i>p</i>	0.046*	0.008*	0.005*	<0.001*	<0.001*
Δ (%)	0.5 ± 5.1	2.6 ± 1.2	-22.6 ± 8.3 <sup>abe</sup>	-31.2 ± 5.0 <sup>ab</sup>	-28.0 ± 7.3 <sup>ab</sup>

C-: non treatment group, C+: diabetic control group, T1: diabetic group and intervened by LVSP dose 0.89 g/BW, T2: diabetic group and intervened by LVSP dose 1.77 g/BW, T3: diabetic group and intervened by astaxanthin 0.09 mg/BW. LVSP: *L. vannamei* shrimp shell powder. The data were written as mean ± SD; *p* value between pre- and post- treatment were analysed using paired *t*-test. Δ (%): percent changes relative to pre-intervention. Differences among the groups were analysed using ANOVA followed by post-hoc Bonferroni. \*Represents a significant different between pre-post intervention. Alphabetical superscripts showed a significance level of <sup>a</sup>*p* < 0.05 compared to C-; <sup>b</sup>*p* < 0.05 compared to C+; <sup>c</sup>*p* < 0.05 compared to T1; <sup>d</sup>*p* < 0.05 compared to T2; <sup>e</sup>*p* < 0.05 compared to T3.

LVSP interventions attenuated total cholesterol by 7% and 30%, respectively (*p* < 0.001). LVSP with high dose showed a comparable lowering effect with AST intervention (*p* > 0.05). Lipoprotein ratios in the present study were indicated by TC-HDL, LDL-HDL, and LDL-TC ratio. Low and high dose of LVSP significantly decreased the ratio of TC-HDL by 45% and 72%, LDL-HDL by 57 and 80%, and LDL-TC by 22 and 31% (*p* < 0.05). LVSP with high dosage exerted a comparable effect as AST.

### 3.3. Adiponectin – plasma atherogenic index association

A coefficient of determination in all biomarkers with adiponectin was shown in Fig. 3A–F. By providing LVSP, the change of total cholesterol levels influenced approximately 72% (*p* < 0.05) of the change adiponectin levels.




Fig. 3. (Continued)

Fig. 3. Correlation between the changes of adiponectin and TC (A), LDL (B), LDL/HDL ratio (C), LDL/TC ratio, TC/HDL ratio (E), and food intake (F). The correlation was taken from the data of groups intervened by LVSP ( $n = 20$ ). The change of value was calculated from the beginning of intervention to the end of intervention. LVSP: *L. vannamei* shrimp shell powder.  $R^2$ : coefficient of determination. Correlation tests were taken using Pearson correlation test.

---

Furthermore, the linear interaction in the groups intervened by LVSP between the decreasing LDL/HDL ratio and increasing adiponectin was shown an approximate 62% ( $p < 0.05$ ). A negative correlation was also shown by the change of TC/HDL ratio to the change adiponectin, which approximately 68% ( $p < 0.05$ ) an increasing adiponectin was determined by TC/HDL ratio.

#### 4. Discussion

To our knowledge, the present study provides the further analysis to confirm the effect of shrimp shells that is considered as by-product to alleviate cardiovascular disease risk in T2DM [20]. Here, we summarised the findings as follows: (1) LVSP treatment maintained the body weight in diabetic condition; (2) LVSP improved lipid profiles; (3) LVSP decreased lipoprotein ratios; (4) negative correlation between adiponectin and all biomarkers was observed.

In the previous study using animal model, the injection of STZ changed body composition, including body size, which is mimicking people with T2DM [22]. In the present study, a significant dropped of body weight was shown in the diabetic group without intervention which is likely associated with the impairment of muscle and splanchnic cells to uptake glucose [23]. We found that LVSP has a capability to sustain the growth in diabetic state similar with the non-diabetic condition. The body weight data in this study support our previous work, showing that both of LVSP treatments increased insulin sensitivity, indicated by decreasing the ratio of TG-HDL [21].

The abnormality of lipid profiles in T2DM has been documented in epidemiological studies [24, 25]. In this animal study, diabetic condition increased the proportion of LDL to total cholesterol about 45%, delineating 28% higher compared to non-diabetic group. The LDL increased by 197% in diabetic group after being exposed by HFD-lard based diet and STZ due to the impairment of insulin sensitivity [21] that affected the function of LDL-receptor [26]. That LVSP intervention markedly reduced the LDL levels hypothesised the bioactive components in LVSP (including astaxanthin) exerts as a hypolipidemic agent in diabetic animals. This result robust the recently published paper that LVSP attenuated dyslipidaemia in diabetic state [20].

The ratio of lipoproteins showed a better prediction on CVD risk compared to conventional lipid levels [27, 28]. Dietary fat has been known to stimulate lipid abnormalities in animal study [29]. In the present study, we found that the increasing of TC/HDL ratio and LDL/HDL ratio in non-diabetic control group due to the raising total cholesterol and LDL levels was mediated by total energy intake. This may infer the amount of energy intake more affecting to raise total cholesterol and LDL levels rather than fat content. Of note, in the certain levels, total cholesterol is required for constructing cell membrane [30]. The increasing LVSP lowered the ratio of TC-HDL, LDL-HDL, and LDL-TC in dose-dependent levels and the magnitude of ratio reduction in the high dose LVSP group came approach to astaxanthin supplement. These pre-clinical results provided the future research of generating powder-based supplement of LVSP. As expected, the predictors of CVD in the presents study were all negatively strong correlation with adiponectin levels. The mechanism underlined the correlations between adiponectin and lipoprotein ratios remains to be elucidated. We hypothesize the association is mediated by increasing HDL and decreasing TG [15, 21].

The effect of shrimp shell on the change of adiponectin levels [21] and the lipid profiles has been reported before [20]. Of note, the method of shrimp shell processing in the current study was different with the previous

report [20], therefore, the effect of shrimp shell in the powder form may result the different outcomes. Here, we add the additional insight that decreasing total cholesterol, TC/HDL ratio, and LDL/HDL ratio are correlated with increasing adiponectin levels. However, we unable to fully delineate the causal relationship among the parameters. Since adiponectin has critical role for endothelium-dependent vasodilation [25], it would be interest to examine whether lipid profiles have a direct impact on adiponectin levels.

As social animals, a single cage might promote stress for rats [31]. Since we prioritised to measure the amount of food intake of every single rat, we put the animals in the single house. Furthermore, the male rodents were prone to fighting, thus we separated the animal in individual house during the intervention periods. Five animals could not survive until the sacrifice day, which was caused by very low food intake, resulting in a reduction in their body weight. Furthermore, a significant increase in the atherogenic index in the C- groups implies the progression of atherosclerosis in normal weight *in vivo* is also influenced by physical activity. This fundamental finding robust the existing observational study in human [32].

In summary, LVSP alleviated the risk of CVD by decreasing LDL, TC, TC/HDL, LDL/HDL, and LDL/TC in T2DM-induced Wistar rats. A high dose of LVSP 1.77 g/BW showed a comparable effect as AST. Whether the higher dose is more beneficial for lipid profiles in diabetic state requires more animal studies. The present study provided the hypolipidemic effect on T2DM that is possible to apply in the human study.

## Acknowledgments

The authors thank the laboratory technicians for their participation.

## Funding statement

The authors report no funding.

## Conflict of interest

There is no conflict of interest declared.

## Authors' contributions

Dewi, L: conceptualization, methodology, software. Ayuningtyas, A: data curation, writing-original draft preparation. Dewi, L: visualization, investigation. Djamiatun, K: supervision, Agustini, TW: supervision, Ayuningtyas, A: software, validation. Dewi, L: writing-reviewing and editing.

## References

- [1] Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? *World J Diabetes*. 2014;5(4):444-70. doi: 10.4239/wjd.v5.i4.444
- [2] Schmidt AM. Diabetes mellitus and cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 2019;39(4):558-68. doi: 10.1161/atvbaha.119.310961
- [3] Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. *Eur J Prev Cardiol*. 2019;26(2\_suppl):25-32. doi: 10.1177/2047487319878371



- [4] Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? *Diabetologia*. 2015;58(5):886-99. doi: 10.1007/s00125-015-3525-8
- [5] Peters SA, Singhathe Y, Mackay D, Huxley RR, Woodward M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: a systematic review and meta-analysis. *Atherosclerosis*. 2016;248:123-31. doi: 10.1016/j.atherosclerosis.2016.03.016
- [6] Ginsberg HN. Lipoprotein physiology. *Endocrinol Metab Clin North Am*. 1998;27(3):503-19. doi: 10.1016/s0889-8529(05)70023-2
- [7] Yadav NK, Thanpari C, Shrewastwa MK, Mittal RK. Comparison of lipid profile in type-2 obese diabetics and obese non-diabetic individuals. a hospital based study from Western Nepal. *Kathmandu Univ Med J (KUMJ)*. 2012;10(39):44-7. doi: 10.3126/kumj.v10i3.8017
- [8] Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. *Vasc Health Risk Manag*. 2009;5:757-65. doi.
- [9] Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. *Curr Med Res Opin*. 2005;21(11):1865-74. doi: 10.1185/030079905x74952
- [10] Panagiotakos DB, Pitsavos C, Skoumas J, Chrysohoou C, Toutouza M, Stefanadis CI, et al. Importance of LDL/HDL cholesterol ratio as a predictor for coronary heart disease events in patients with heterozygous familial hypercholesterolaemia: a 15-year follow-up (1987–2002). *Curr Med Res Opin*. 2003;19(2):89-94. doi.
- [11] Quispe R, Elshazly MB, Zhao D, Toth PP, Puri R, Virani SS, et al. Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. *Eur J Prev Cardiol*. 2020;27(15):1597-605. doi: 10.1177/2047487319862401.
- [12] Caselli C. Role of adiponectin system in insulin resistance. *Mol Genet Metab*. 2014;113(3):155-60. doi: 10.1016/j.ymgme.2014.09.003.
- [13] Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius Br. Serum adiponectin Is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. *J Clin Endocrinol Metab*. 2007;92(2):571-6. doi: 10.1210/jc.2006-1067
- [14] Koenig W, Khuseynova N, Baumert J, Meisinger C, Löwel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. *J Am Coll Cardiol*. 2006;48(7):1369-77. doi: 10.1016/j.jacc.2006.06.053
- [15] Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism. *Obes Rev*. 2013;14(12):939-49. doi: 10.1111/obr.12064
- [16] Vázquez JA, Ramos P, Mirón J, Valcarcel J, Sotelo CG, Pérez-Martín RI. Production of chitin from *Penaeus vannamei* by-products to pilot plant scale using a combination of enzymatic and chemical processes and subsequent optimization of the chemical production of chitosan by response surface methodology. *Mar Drugs*. 2017;15(6). doi: 10.3390/md15060180
- [17] Khoushab F, Yamabhai M. Chitin research revisited. *Mar Drugs*. 2010;8(7):1988-2012. doi: 10.3390/md8071988
- [18] Shahidi F, Metusalach, Brown JA. Carotenoid pigments in seafoods and aquaculture. *Crit Rev Food Sci Nutr*. 1998;38(1):1-67. doi: 10.1080/10408699891274165
- [19] Sila A, Ghilissi Z, Kamoun Z, Makni M, Nasri M, Bougatef A, et al. Astaxanthin from shrimp by-products ameliorates nephropathy in diabetic rats. *Eur J Nutr*. 2015;54(2):301-7. doi: 10.1007/s00394-014-0711-2
- [20] Huang CH, Lin CH, Huang HH, Tsai GJ. Development of fermented shrimp shell product with hypoglycemic and hypolipidemic effects on diabetic rats. *Metabolites*. 2022;12(8). doi: 10.3390/metabo12080695
- [21] Ayuningtyas A, Agustini TW, Djamiatun K. Whiteleg shrimp shell powder ameliorates adiponectin and triglyceride-to-HDL ratio in type 2 diabetic rats. *NFS*. 2020;50(4):617-29. doi: 10.1108/NFS-04-2019-0138
- [22] Lin YH, Tsai SC, Chuang SJ, Harris MB, Masodsai K, Chen PN, et al. Whole-life body composition trajectory and longevity: role of insulin. *Aging (Albany NY)*. 2021;13(7):9719-31. doi: 10.18632/aging.202727
- [23] Basu A, Basu R, Shah P, Vella A, Johnson CM, Jensen M, et al. Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity. *Diabetes*. 2001;50(6):1351-62. doi: 10.2337/diabetes.50.6.1351
- [24] Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. *Lipids Health Dis*. 2014;13:183. doi: 10.1186/1476-511x-13-183
- [25] Antwi-Baffour S, Kyeremeh R, Boateng SO, Annison L, Seidu MA. Haematological parameters and lipid profile abnormalities among patients with type-2 diabetes mellitus in Ghana. *Lipids Health Dis*. 2018;17(1):283. doi: 10.1186/s12944-018-0926-y
- [26] Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. *Diabetes Care*. 1991;14(9):839-55. doi: 10.2337/diacare.14.9.839
- [27] Zhu L, Lu Z, Zhu L, Ouyang X, Yang Y, He W, et al. Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people. *Kardiol Pol*. 2015;73(10):931-8. doi: 10.5603/KP.a2015.0086
- [28] Barzi F, Patel A, Woodward M, Lawes CM, Ohkubo T, Gu D, et al. A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region. *Ann Epidemiol*. 2005;15(5):405-13. doi: 10.1016/j.annepidem.2005.01.005

- [29] Chen B, Huang Y, Zheng D, Ni R, Bernards MA. Dietary fatty acids alter lipid profiles and induce myocardial dysfunction without causing metabolic disorders in mice. *Nutrients*. 2018;10(1). doi: 10.3390/nu10010106
- [30] Krause MR, Regen SL. The structural role of cholesterol in cell membranes: from condensed bilayers to lipid rafts. *Acc Chem Res*. 2014;47(12):3512-21. doi: 10.1021/ar500260t
- [31] Manouze H, Ghestem A, Poillerat V, Bennis M, Ba-M'hamed S, Benoliel JJ, et al. Effects of single cage housing on stress, cognitive, and seizure parameters in the rat and mouse pilocarpine models of epilepsy. *eNeuro*. 2019;6(4). doi: 10.1523/eneuro.0179-18.2019
- [32] Crichton GE, Alkerwi A. Physical activity, sedentary behavior time and lipid levels in the Observation of Cardiovascular Risk Factors in Luxembourg study. *Lipids Health Dis*. 2015;14:87. doi: 10.1186/s12944-015-0085-3

AUTHOR COPY